
Actinium Pharmaceuticals Inc (AMEX:ATNM) shares are trading higher Tuesday morning after the company announced it entered into a license and supply agreement with Immedica Pharma for Iomab-B.
Actinium will receive an upfront payment of $35 million and will be eligible for an additional $417 million in regulatory and commercial milestones as well as royalties in the mid-20% range on net sales.